These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 8027412

  • 1. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
    Tollefson GD, Rampey AH, Beasley CM, Enas GG, Potvin JH.
    J Clin Psychopharmacol; 1994 Jun; 14(3):163-9. PubMed ID: 8027412
    [Abstract] [Full Text] [Related]

  • 2. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
    Goldstein DJ, Rampey AH, Potvin JH, Masica DN, Beasley CM.
    J Clin Psychiatry; 1993 Aug; 54(8):309-16. PubMed ID: 8253699
    [Abstract] [Full Text] [Related]

  • 3. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    Tollefson GD, Holman SL, Sayler ME, Potvin JH.
    J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
    [Abstract] [Full Text] [Related]

  • 4. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
    Tollefson GD, Sayler ME.
    Depress Anxiety; 1994 Feb; 4(6):294-311. PubMed ID: 9166658
    [Abstract] [Full Text] [Related]

  • 5. Lack of association between fluoxetine and suicidality in bulimia nervosa.
    Wheadon DE, Rampey AH, Thompson VL, Potvin JH, Masica DN, Beasley CM.
    J Clin Psychiatry; 1992 Jul; 53(7):235-41. PubMed ID: 1639742
    [Abstract] [Full Text] [Related]

  • 6. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
    Wernicke JF, Sayler ME, Koke SC, Pearson DK, Tollefson GD.
    Depress Anxiety; 1997 Jul; 6(1):31-9. PubMed ID: 9394873
    [Abstract] [Full Text] [Related]

  • 7. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS, Benazzi F, Perugi G, Rihmer Z.
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [Abstract] [Full Text] [Related]

  • 8. Suicidality and fluoxetine: is there a relationship?
    Fava M, Rosenbaum JF.
    J Clin Psychiatry; 1991 Mar; 52(3):108-11. PubMed ID: 2005073
    [Abstract] [Full Text] [Related]

  • 9. Fluoxetine: activating and sedating effects.
    Beasley CM, Potvin JH.
    Int Clin Psychopharmacol; 1993 Mar; 8(4):271-5. PubMed ID: 8277147
    [Abstract] [Full Text] [Related]

  • 10. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
    Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN.
    BMJ; 1991 Sep 21; 303(6804):685-92. PubMed ID: 1833012
    [Abstract] [Full Text] [Related]

  • 11. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA, Brecher M, Paulsson B.
    Bipolar Disord; 2006 Oct 21; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [Abstract] [Full Text] [Related]

  • 12. Does the FDA proposed list of possible correlates of suicidality associated with antidepressants apply to an adult private practice population?
    Akiskal HS, Benazzi F.
    J Affect Disord; 2006 Aug 21; 94(1-3):105-10. PubMed ID: 16766043
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
    Tollefson GD, Fawcett J, Winokur G, Beasley CM, Potvin JH, Faries DE, Rampey AH, Sayler ME.
    Ann Clin Psychiatry; 1993 Dec 21; 5(4):209-24. PubMed ID: 8312978
    [Abstract] [Full Text] [Related]

  • 14. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
    Tourian KA, Padmanabhan K, Groark J, Ninan PT.
    J Clin Psychopharmacol; 2010 Aug 21; 30(4):411-6. PubMed ID: 20631558
    [Abstract] [Full Text] [Related]

  • 15. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J.
    Clin Ther; 2004 Sep 21; 26(9):1446-55. PubMed ID: 15531007
    [Abstract] [Full Text] [Related]

  • 16. Fluoxetine: activating and sedating effects at multiple fixed doses.
    Beasley CM, Sayler ME, Weiss AM, Potvin JH.
    J Clin Psychopharmacol; 1992 Oct 21; 12(5):328-33. PubMed ID: 1479050
    [Abstract] [Full Text] [Related]

  • 17. Antidepressant drug use: differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine.
    Dittmann RW, Linden M, Osterheider M, Schaaf B, Ohnmacht U, Weber HJ.
    Pharmacopsychiatry; 1997 Jan 21; 30(1 Suppl):28-34. PubMed ID: 9035225
    [Abstract] [Full Text] [Related]

  • 18. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A.
    Clin Neurol Neurosurg; 2005 Oct 21; 107(6):497-508. PubMed ID: 15922506
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
    Sandor P, Baker B, Irvine J, Dorian P, McKessok D, Mendlowitz S.
    Depress Anxiety; 1998 Oct 21; 7(2):69-72. PubMed ID: 9614594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.